RTP Mobile Logo
International Second Opinion — Part I: Case-Based Discussions Focused on the Management of Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
Released March 2013

Proceedings from Part I of a 2-part satellite symposia series during the 54th ASH Annual Meeting. Including perspectives from Drs John P Leonard, Myron S Czuczman, Martin Dreyling, Steven M Horwitz and Mitchell R Smith. (Video Program)

CE Disclosures and Faculty Information


    This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of non-Hodgkin lymphoma (NHL)/chronic lymphocytic leukemia (CLL).


    Taken together, it is estimated that approximately 148,040 new lymphoid and myeloid cancer cases were identified in the United States in the year 2012, and 54,380 individuals died from these diseases. Of importance, currently more than 50 drug products are labeled for use in the management of hematologic cancers, with more than 60 distinct FDA-approved indications. Although this extensive list of available treatment options is reassuring for patients and oncology healthcare professionals, it poses a challenge to the practicing clinician who must maintain up-to-date knowledge of appropriate clinical management strategies across a vast spectrum of liquid and solid tumors.

    These proceedings from a CME symposium during the 54th ASH Annual Meeting use the perspectives of renowned experts in the field of hematologic oncology on cases provided by an international panel of community oncologists from the United States, India, Italy and Spain to frame a relevant discussion of the optimal management of various forms of NHL. By providing information on the latest research developments and their potential application to routine practice, this activity is designed to assist hematologists, medical oncologists and hematology-oncology fellows with the formulation of up-to-date clinical management strategies for NHL and CLL.

    • Appraise recent data on therapeutic advances and changing practice standards in NHL, including CLL, and integrate this information, as appropriate, into current clinical care.
    • Use prognostic and predictive clinical and molecular markers to aid in treatment decision-making for NHL.
    • Apply the results of emerging clinical research to the selection of optimal systemic therapy for patients with newly diagnosed and relapsed or refractory CLL.
    • Identify patients with NHL who may benefit from maintenance systemic treatment.
    • Recognize the role of romidepsin, pralatrexate, brentuximab vedotin and other novel agents in the management of peripheral T-cell lymphoma and/or advanced-stage cutaneous T-cell lymphoma, and educate patients about their associated benefits and risks.
    • Recall new data with investigational agents demonstrating promising activity in NHL.
    • Assess ongoing clinical trials evaluating innovative investigational approaches for NHL, and counsel appropriate patients for study participation.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue


    CME credit is no longer available for this issue


    This CME activity consists of a video component. The participant should watch the video.

    CME credit is no longer available for this issue


    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

    John P Leonard, MD
    Richard T Silver Distinguished Professor of Hematology and Medical Oncology
    Associate Dean for Clinical Research
    Weill Cornell Medical College
    New York, New York

    Consulting Agreements: Celgene Corporation, Cephalon Inc, Genentech BioOncology, GlaxoSmithKline, Millennium: The Takeda Oncology Company.

    Myron S Czuczman, MD
    Chief, Lymphoma/Myeloma Service
    Head, Lymphoma Translational Research Laboratory
    Roswell Park Cancer Institute
    Professor of Medicine
    School of Medicine and Biomedical Sciences
    State University of New York at Buffalo
    Buffalo, New York

    Advisory Committee: Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation, Genentech BioOncology, Onyx Pharmaceuticals Inc.

    Martin Dreyling, MD, PhD

    Professor of Medicine
    Department of Medicine III
    University Hospital — LMU Munich
    Munich, Germany

    Advisory Committee, Investigator Initiated Trial Support and Speakers Bureau: Celgene Corporation, Mundipharma International Limited, Pfizer Inc, Roche Laboratories Inc.

    Steven M Horwitz, MD
    Assistant Attending
    Lymphoma Service, Division of Hematologic Oncology
    Memorial Sloan-Kettering Cancer Center
    New York, New York

    Advisory Committee: Allos Therapeutics, Celgene Corporation; Consulting Agreements: Allos Therapeutics, Bristol-Myers Squibb Company, Celgene Corporation, Kyowa Hakko Kirin Co Ltd, Seattle Genetics, Spectrum Pharmaceuticals Inc; Paid Research: Allos Therapeutics, Celgene Corporation, Kyowa Hakko Kirin Co Ltd, Millennium: The Takeda Oncology Company, Seattle Genetics, Spectrum Pharmaceuticals Inc.

    Mitchell R Smith, MD, PhD
    Director of Lymphoid Malignancies at Cleveland Clinic
    Cleveland, Ohio

    Advisory Committee: Cephalon Inc; Speakers Bureau: Allos Therapeutics, Cephalon Inc, Genentech BioOncology, Millennium: The Takeda Oncology Company, Spectrum Pharmaceuticals Inc.

    CONSULTING ONCOLOGISTS — The following consulting oncologists (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Warren S Brenner, MBBCh
    Center for Hematology/Oncology
    Lynn Cancer Institute
    Boca Raton, Florida

    Speakers Bureau: Celgene Corporation, Millennium: The Takeda Oncology Company; Stock Ownership: Celgene Corporation.

    Ramón García-Sanz, MD, PhD

    Department of Hematology
    Hospital Universitario de Salamanca
    Salamanca, Spain

    No real or apparent conflicts of interest to disclose.

    Alberto Grossi, MD
    Unit of Hematology
    Istituto Fiorentino di Cura e Assistenza (IFCA)
    Florence, Italy 

    No real or apparent conflicts of interest to disclose.

    Vineet Gupta, MD
    Principal Consultant, Medical Oncology
    Max Super Speciality Hospital
    Delhi, India

    No real or apparent conflicts of interest to disclose.

    Elizabeth D Simmons, MD
    Physician Lead of Service, Hematology/Medical Oncology
    Kaiser Permanente
    Bellflower, California
    Volunteer Faculty
    Harbor-UCLA Medical Center, Hematology
    Torrance, California

    No real or apparent conflicts of interest to disclose.

    MODERATORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Algeta US, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Foundation Medicine Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly USA LLC, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva Oncology.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Celgene Corporation, Genentech BioOncology/Biogen Idec, Gilead Sciences Inc, Millennium: The Takeda Oncology Company, Mundipharma International Limited and Teva Oncology.

    Hardware/Software Requirements:
    A high-speed Internet connection

    A monitor set to 1280 x 1024 pixels or more

    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later

    Adobe Flash Player 10.2 plug-in or later

    Adobe Acrobat Reader

    (Optional) Sound card and speakers for audio

Acknowledge and close

Watch video
(WiFi is recommended for best performance):

Introduction: Dr Love
Module 1:
Dr Leonard –
Follicular Lymphoma
Module 2:
Dr Czuczman –
Diffuse Large B-Cell Lymphoma
Module 3:
Dr Dreyling –
Mantle-Cell Lymphoma
Module 4:
Dr Horwitz –
T-Cell Lymphoma
Module 5:
Dr Smith –
Chronic Lymphocytic Leukemia